Log in
Enquire now
‌

US Patent 9873894 Methods and compositions for treatment of a genetic condition

Patent 9873894 was granted and assigned to Sangamo Therapeutics on January, 2018 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
Current Assignee
Sangamo Therapeutics
Sangamo Therapeutics
Date Filed
May 15, 2014
Date of Patent
January 23, 2018
Patent Application Number
14278903
Patent Citations Received
‌
US Patent 12123032 CRISPR enzyme mutations reducing off-target effects
0
‌
US Patent 12018275 Delivery and use of the CRISPR-CAS systems, vectors and compositions for hepatic targeting and therapy
0
‌
US Patent 12110545 Methods of assessing nuclease cleavage
0
‌
US Patent 11667911 Use of exonucleases to improve CRISPR/CAS-mediated genome editing
0
‌
US Patent 11680268 Methods for improving CRISPR/Cas-mediated genome-editing
0
‌
US Patent 11690921 Delivery of target specific nucleases
0
‌
US Patent 11708572 Acoustic cell separation techniques and processes
0
‌
US Patent 11759480 Compositions and methods for CAR T cell therapy
‌
US Patent 11779602 Methods of use for CAR T cells
‌
US Patent 11834686 Engineered target specific base editors
0
•••
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
9873894
Patent Primary Examiner
‌
Antonio Galisteo Gonzalez

Find more entities like US Patent 9873894 Methods and compositions for treatment of a genetic condition

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.